Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Brady Dougan Biography and Net Worth

Director of Humacyte

Mr. Dougan served as the chair of the Humacyte Board from March 2019 to August 2021, and as a member of its Board of Directors since 2005. Mr. Dougan holds a B.A. in Economics and an M.B.A. in Finance from the University of Chicago. Mr. Dougan has been a member of Humacyte’s Board since the Company’s founding.

What is Brady W. Dougan's net worth?: The estimated net worth of Brady W. Dougan is at least $9.24 million as of November 19th, 2024. Mr. Dougan owns 1,992,253 shares of Humacyte stock worth more than $9,244,054 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Dougan may own. Learn More about Brady W. Dougan's net worth.
How do I contact Brady W. Dougan?: The corporate mailing address for Mr. Dougan and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Brady W. Dougan's contact information.
Has Brady W. Dougan been buying or selling shares of Humacyte?: In the last ninety days, Brady W. Dougan has sold $1,855,172.06 in Humacyte stock. Most recently, Brady W. Dougan sold 427,459 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a transaction totalling $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company's stock, valued at $8,646,378.02. Learn More on Brady W. Dougan's trading history.
Who are Humacyte's active insiders?: Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.
Are insiders buying or selling shares of Humacyte?: During the last twelve months, Humacyte insiders bought shares 4 times. They purchased a total of 59,012 shares worth more than $389,301.20. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 4,212,973 shares worth more than $25,940,916.90. The most recent insider tranaction occured on December, 4th when Director Michael T Constantino bought 4,600 shares worth more than $20,194.00. Insiders at Humacyte own 11.2% of the company. Learn More about insider trades at Humacyte.
Information on this page was last updated on 12/4/2024.

Brady W. Dougan Insider Trading History at Humacyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Sell	427,459	$4.34	$1,855,172.06	1,992,253
8/29/2024	Sell	352,112	$6.35	$2,235,911.20	3,677,262
8/27/2024	Sell	252,676	$6.71	$1,695,455.96	4,306,464
6/12/2024	Sell	271,518	$7.30	$1,982,081.40	4,559,140
6/4/2024	Buy	2,362	$6.35	$14,998.70	240,832
8/18/2023	Sell	626,979	$3.57	$2,238,315.03	8,793,583
12/16/2022	Sell	239,538	$2.53	$606,031.14	17,990,736
12/14/2022	Sell	276,304	$2.76	$762,599.04	18,323,700
9/15/2022	Sell	1,522,500	$4.00	$6,090,000.00	18,930,004
12/16/2021	Sell	75,000	$9.00	$675,000.00
12/14/2021	Sell	100,000	$9.44	$944,000.00

Brady W. Dougan Buying and Selling Activity at Humacyte

Humacyte Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Today's Range

Now: $4.64

$4.45

$6.77

50 Day Range

MA: $4.83

$3.46

$5.82

2 Week Range

Now: $4.64

$2.48

$9.97

Volume

75,231,266 shs

Average Volume

2,735,148 shs

Market Capitalization

$583.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.